clinical trial · NCT06614153
Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
Jiangsu HengRui Medicine Co., Ltd.·phase2·completed·n = 61
Parkinson's DiseaseHRG2010(I)HRG2010(II)Sustained-release Carbidopa/Levodopa
brief summary
The study is a multicenter, randomized, open-label, active-controlled, Phase II clinical study. The aim of this trial is to evaluated the pharmacokinetics, pharmacodynamics,efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease Patients With Motor Fluctuations.
started
May 16, 2023
primary completion
Jan 31, 2024
completion
Mar 4, 2024
last updated
Sep 26, 2024
official title
A Randomized, Open-label, Controlled, Single-dose, Multiple-dose Phase II Study to Evaluate the Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol